Analyzing Phathom Pharmaceuticals (NASDAQ:PHAT) & OS Therapies (NYSE:OSTX)

OS Therapies (NYSE:OSTX) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Earnings and Valuation

This table compares OS Therapies and Phathom Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OS Therapies	N/A	N/A	-$7.79 million	N/A	N/A
Phathom Pharmaceuticals	$55.25 million	8.08	-$201.59 million	($5.35)	-1.20

OS Therapies has higher earnings, but lower revenue than Phathom Pharmaceuticals.

Profitability

This table compares OS Therapies and Phathom Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OS Therapies	N/A	N/A	-569.57%
Phathom Pharmaceuticals	-1,292.14%	N/A	-79.57%

Institutional and Insider Ownership

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 13.8% of OS Therapies shares are owned by company insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for OS Therapies and Phathom Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OS Therapies	0	0	2	2	3.50
Phathom Pharmaceuticals	0	1	4	1	3.00

OS Therapies presently has a consensus target price of $17.50, suggesting a potential upside of 1,007.59%. Phathom Pharmaceuticals has a consensus target price of $22.17, suggesting a potential upside of 245.81%. Given OS Therapies’ stronger consensus rating and higher possible upside, analysts clearly believe OS Therapies is more favorable than Phathom Pharmaceuticals.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.